TGFB1 and breast cancer: This is evident by the effects of Coco, a TGFβ1 ligand antagonist, in metastatic sites of the lung, resulting in re-activation of breast cancer cells, but not in brain or bone metastases (Figure 3, Table 1) [117,118].